IL17A and Psoriasiform dermatitis: Pharmacological restoration of the axis also has a proof-of-concept: a stable form of galectin-9 (a TIM3 ligand) suppresses contact hypersensitivity and IL-23–driven psoriasiform dermatitis, reducing IL-17/IL-22 and epidermal STAT3 activation [30].